NEW YORK (GenomeWeb News) – Lab21, a Cambridge, UK-based clinical lab and companion diagnostics developer, has purchased a majority share of molecular diagnostics firm Biotec Laboratories.
The Ipswich, UK-based diagnostics firm has focused on infectious diseases since its creation in 1993. It also has been distributing some of Lab21's diagnostics products through its global network of distributors in 80 countries.
The acquisition includes Biotec Laboratories SA, the South African subsidiary of the firm. The subsidiary has developed a phage amplification technology that it is using in the development of rapid tests for active and drug-resistant tuberculosis.
"We look forward to working with the R&D team of Biotec and exploring how its phage amplification technology can be used for the detection of other mycobacterium borne diseases, beyond TB," Lab21 Chief Scientific Development Officer Berwyn Clarke said in a statement. "The combination of our technical and clinical skills and sector experience creates a very strong R&D group that can fuel significant new product development in both immunodiagnostics and molecular diagnostics over the coming years."
Financial terms of the deal were not disclosed.
Biotec Laboratories will operate as a subsidiary of Lab21.